Concomitant Gastrointestinal Bleeding Prophylaxis With Dual Antiplatelet Therapy Usage.

Area of Science:

• Gastroenterology and Pharmacology
• Clinical Therapeutics
• Evidence-Based Medicine

Background:

• Gastrointestinal bleeding (GIB) is a significant risk for patients on dual antiplatelet therapy (DAPT).
• Proton pump inhibitors (PPIs) are standard for GIB prophylaxis but may interact with clopidogrel.
• Histamine-2 receptor antagonists (H2RAs) are explored as alternatives, especially with comorbidities.

Purpose of the Study:

• To review and compare the efficacy and safety of PPIs versus H2RAs for GIB prevention in DAPT patients.
• To explore emerging alternatives like potassium-competitive acid blockers (PCABs).
• To emphasize the need for personalized GIB prophylaxis strategies.

Main Methods:

• Comprehensive literature review of comparative studies on GIB prophylaxis in DAPT patients.
• Analysis of efficacy, safety profiles, and drug-interaction data for PPIs and H2RAs.
• Inclusion of recent findings on PCABs and patient-specific factors.

Main Results:

• PPIs are effective but carry risks of clopidogrel interaction via CYP2C19.
• H2RAs show potential benefits in specific patient subgroups, including those with cardiovascular or renal issues.
• PCABs represent a promising new class for GIB prevention.

Conclusions:

• Optimal GIB prophylaxis in DAPT patients requires individualized treatment plans.
• Balancing efficacy, safety, and drug interactions is crucial for patient management.
• Further large-scale research is needed to refine clinical guidelines and address data gaps.